TD Cowen Keeps Their Buy Rating on Gap Inc (GAP)
In a report released today, Jonna Kim from TD Cowen maintained a Buy rating on Gap Inc (GAP – Research Report). The company's shares closed today at $22.33.
Confident Investing Starts Here:
Kim covers the Consumer Cyclical sector, focusing on stocks such as American Eagle, Gap Inc, and Bath & Body Works. According to TipRanks, Kim has an average return of 21.7% and a 44.12% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Gap Inc with a $28.33 average price target, implying a 26.90% upside from current levels. In a report released today, Morgan Stanley also maintained a Buy rating on the stock with a $27.00 price target.
See Insiders' Hot Stocks on TipRanks >>
Based on Gap Inc's latest earnings release for the quarter ending February 1, the company reported a quarterly revenue of $4.15 billion and a net profit of $206 million. In comparison, last year the company earned a revenue of $4.3 billion and had a net profit of $185 million
Based on the recent corporate insider activity of 80 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of GAP in relation to earlier this year. Most recently, in March 2025, Elisabeth B Donohue, a Director at GAP sold 3,539.00 shares for a total of $74,460.56.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
23 minutes ago
- Globe and Mail
UnitedHealth Declines 40.4% YTD: Here's Why it's Still Not a Bargain
UnitedHealth Group Incorporated UNH shares have tumbled 25.4% in the past month alone, bringing their year-to-date loss to 40.4%. That's well below the performance of both the broader industry (-29.2%) and the S&P 500 (flat). Among its peers, Humana Inc. HUM has declined just 8.1% and Elevance Health, Inc. ELV has gained 4%, underscoring UNH's uniquely sharp decline. Historically considered a defensive healthcare stock, UnitedHealth's consistent earnings, stable dividend, and low beta (0.45) made it a favorite among risk-averse, long-term investors. But this year's selloff may not be a buying opportunity; it looks more like catching a falling knife. UNH's Mounting Headwinds UnitedHealth is facing simultaneous pressures across multiple business lines. The company missed both earnings and revenue estimates in the first quarter and withdrew its 2025 financial guidance. Meanwhile, rising medical costs, especially in the Medicare Advantage segment, continue to compress margins. Higher-than-expected patient volumes, particularly high-acuity cases, have further strained profitability. Moreover, CEO Andrew Witty stepped down, prompting the return of longtime executive Stephen Hemsley. Soon after, a Wall Street Journal report revealed a criminal investigation into alleged Medicare fraud. Additional setbacks include a major expansion of Medicare Advantage audits by the Centers for Medicare and Medicaid Services, raising the risk of penalties and reimbursement clawbacks. While Hemsley's $25 million stock purchase offered brief reassurance, the bounce was short-lived. The stock fell again after reports emerged alleging the company secretly incentivized nursing homes to avoid hospital transfers, an accusation the Department of Justice declined to pursue due to insufficient evidence, but one that damaged UNH's reputation nonetheless. Investor sentiment is rapidly Zacks Consensus Estimate for UNH's 2025 EPS has seen 12 downward revisions in the past month, while the 2026 EPS estimate has seen 10, without a single upward revision. Earnings for 2025 are now projected to decline by 17.3%, even as revenues are still expected to climb 12.9% year over year. (See the Zacks Earnings Calendar to stay ahead of market-making news.) UNH Not Cheap Enough to Chase At first glance, UnitedHealth appears attractively priced, trading at a forward P/E of 12.31X, well below its five-year median of 19.20X. However, that multiple still sits above the industry average of 11.50X. By comparison, Humana trades at 15.18X and Elevance at 10.54X, placing UnitedHealth somewhere in the middle despite the selloff. But valuation alone is not enough to justify entry. Regulatory risk, cost pressures and reputational damage pose real threats to the company's business model. Optum Rx, UNH's pharmacy benefit manager, may also face headwinds from regulatory moves targeting PBMs' pricing power. President Trump's "most-favored nation" executive order will likely affect 'middlemen' and facilitate the direct sale of drugs to patients. Whether these issues mark a temporary rough patch or signal deeper structural challenges remains to be seen. Either way, the margin of safety appears thin at the moment. Is There a Path Forward for UnitedHealth? Despite the turmoil, UnitedHealth retains significant competitive advantages. Its vertically integrated model, scale, and investments in AI and digital health position it to navigate long-term industry trends. Medicare Advantage rate increases in 2026 could provide some relief to margins. As of March 31, 2025, UnitedHealthcare served 50.1 million members, up 1.9% year over year, driven by growth in self-funded commercial plans. U.S. healthcare spending continues to rise with an aging population and increasing chronic disease rates, trends that ultimately play to UnitedHealth's strengths. Financially, the company remains on solid footing. It generated $5.5 billion in operating cash flow in the first quarter, up significantly from $1.1 billion the year prior and ended the quarter with $34.3 billion in cash and short-term investments. It also returned over $5 billion to shareholders through dividends and stock buybacks. Final Verdict: Wait for Stability UnitedHealth's near-term outlook remains clouded by a series of setbacks, including regulatory probes, leadership change, rising costs and the withdrawal of 2025 guidance. While the company maintains a strong market position and generates solid cash flow, these challenges have sharply undermined investor confidence. Ongoing legal scrutiny and continued earnings downgrades have only deepened uncertainty around a potential recovery. With no clear catalysts in sight and the stock underperforming significantly, UnitedHealth carries a Zacks Rank #5 (Strong Sell). Investors may be better served waiting for signs of stabilization before re-entering. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Humana Inc. (HUM): Free Stock Analysis Report Elevance Health, Inc. (ELV): Free Stock Analysis Report
Globe and Mail
23 minutes ago
- Globe and Mail
Green Country Pest Control Announces New Operations Manager
Green Country Pest Control has named Brandon Green as its new Operations Manager, bringing extensive industry experience and a strong track record of growth and operational leadership. Previously VP of Operations at Perfect Pest Control-Texas, Brandon helped triple that company's customer base and boost revenue by over $2 million in under a year. At Green Country, he is already implementing process improvements aimed at enhancing service quality and operational efficiency. Alvin, Texas - Jun 2, 2025 - Green Country Pest Control is excited to announce the hiring of Brandon Green as the new Operations Manager. With years of industry experience and a passion for driving operational excellence, Brandon has already begun implementing significant changes that will elevate Green Country Pest Control to new heights. Additionally, the company is proud to promote Colin Banks to Field Supervisor, recognizing his exceptional work and dedication to customer service. Brandon joins Green Country Pest Control with a proven track record in the pest control industry. He most recently served as Vice President of Operations at Perfect Pest Control-Texas, where he played a key role in tripling the company's customer base and increasing revenue by over $2 million in just 11 months. His expertise in creating operational procedures and training materials has been invaluable to the success of the organizations he's worked with. In his new role, Brandon will focus on streamlining Green Country Pest Control's operations, improving processes, and enhancing the overall customer experience. His leadership is already transforming the way the company conducts business, and he is committed to fostering growth and setting new standards for pest control services in Alvin and beyond. "I'm thrilled to be a part of Green Country Pest Control and to contribute to its ongoing success," said Brandon Green. "I believe in empowering teams, optimizing operational efficiency, and continuously striving for excellence. Together, we will provide top-tier pest control solutions and exceptional service to every customer." In addition to Brandon's appointment, Green Country Pest Control is pleased to announce the promotion of Colin Banks to Field Supervisor. Colin has shown outstanding dedication to the company and its customers, and this promotion recognizes his hard work, leadership skills, and commitment to excellence in the field. Owner Read Flake expressed his confidence in the company's future under the new leadership. "Brandon's extensive experience in the pest control industry, along with Colin's well-deserved promotion, positions us for continued growth and success. We are excited for what lies ahead under their direction." For more information about Green Country Pest Control and its services, please visit Contact: Green Country Pest Control Owner: Read Flake Phone: 281-888-8605 Email: service@ Website: Media Contact Company Name: Green Country Pest Control Contact Person: Read Flake Email: Send Email Phone: (281) 888-8605 Address: 1600 E Hwy 6 ste 401 City: Alvin State: Texas Country: United States Website:
Globe and Mail
25 minutes ago
- Globe and Mail
Gold Is Bullish, But Be Aware Of Deeper Intraday Pullback; Elliott Wave Intraday Analysis
Good morning traders! USDollar Index - DXY remains under intraday bearish pressure at the start of the month and week, so we are definitely still bearish and expect more weakness, but it's early Monday and we may not see straight lines, thus still be aware of bigger or more complex intraday pullback before a bearish continuation. DXY could actually still be trading in subwave (b) and it can still see higher intraday resistance for subwave (c) of "ii", which can fill the GAP from May 18 before real bears show up. However, of course, if DXY breaks below 98 area decisively, then more weakness can be seen within wave "iii" of 5, unless it goes sideways for a higher degree bearish triangle in wave 4. Gold is coming nicely higher for wave subwave »c« of a projected three-wave abc corrective recovery in wave B and it's now testing key resistance, from where we may see another sell-off for a wave C of a higher degree wave (2), especially if we consider a new open GAP at 3925 level and then prevoius one at 3200 area, which can act as a strong support. However, if gold breaks straight above 3367 level decisively, then higher degree wave (3) can be already in full progress.
